{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:55:56Z","timestamp":1767135356334,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd013474","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000}}],"reference-count":227,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013474.pub2","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T06:26:13Z","timestamp":1704349573000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maintenance therapy for chronic lymphocytic leukaemia"],"prefix":"10.1002","volume":"2024","author":[{"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ying","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Chuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Public Health; National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fen","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Chun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[{"name":"Department of Neurology; Changhua Christian Hospital; Changhua Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine; Tri-Service General Hospital, National Defense Medical Center; Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"14","key":"10.1002\/14651858.CD013474.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/bloodadvances.2017015396","article-title":"Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)","volume":"2","author":"Byrd J","year":"2018","journal-title":"Blood Advance"},{"issue":"11","key":"10.1002\/14651858.CD013474.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2352-3026(17)30168-0","article-title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Chanan-Khan A","year":"2017","journal-title":"Lancet Haematology"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S2352-3026(17)30235-1","article-title":"Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study","volume":"5","author":"Dartigeas","year":"2018","journal-title":"Lancet Haematology"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1016\/S2352-3026(17)30171-0","article-title":"Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study","volume":"4","author":"Fink A","year":"2017","journal-title":"Lancet Haematology"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.23668","article-title":"Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients","volume":"89","author":"Foa","year":"2014","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/cam4.1980","article-title":"Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial","volume":"8","author":"Egle","year":"2019","journal-title":"Cancer Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(16)30045-X","article-title":"Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial","volume":"3","author":"Greil","year":"2016","journal-title":"Lancet Haematology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3109\/10428194.2015.1122783","article-title":"Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia","volume":"57","author":"Osterborg","year":"2016","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0009|cit9","unstructured":"A study to assess the effect of maintenance treatment with rituximab versus no treatment in participants with progressive B-cell chronic lymphocytic leukemia (CLL) ClinicalTrials.gov\/show\/NCT00718549"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/ejh.13042","article-title":"Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial","volume":"100","author":"Robak","year":"2018","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer C","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission \u2013 experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner C","year":"2004","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0013|cit13","unstructured":"Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG) ClinicalTrials.gov\/show\/NCT01039376"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-019-0260-2","article-title":"Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study","volume":"9","author":"Van Oers","year":"2019","journal-title":"Blood Cancer Journal"},{"issue":"13","key":"10.1002\/14651858.CD013474.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"Oers","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"Williams M","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"24","key":"10.1002\/14651858.CD013474.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-05-502773","article-title":"Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia","volume":"122","author":"Abrisqueta","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.13957","article-title":"Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study","volume":"173","author":"Chang J","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-018-3380-z","article-title":"Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide\/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I\/II study","volume":"97","author":"Egle","year":"2018","journal-title":"Annual Hematology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0020|cit20","unstructured":"First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001569-33\/ES"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0021|cit21","unstructured":"Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) \u2013 len-cam www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-001823-71\/IT"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0022|cit22","unstructured":"Rituximab-2cda + rituximab maintenance in chronic lymphocytic leukaemia and small lymphocytic lymphoma www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-018519-14\/IT"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0023|cit23","unstructured":"A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000569-35\/DE"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0024|cit24","unstructured":"A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax, GDC-0199) followed by ABT-199 and GA101 maintenance in CLL patients www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000580-40\/DE"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0025|cit25","unstructured":"A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000582-47\/DE"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0026|cit26","unstructured":"A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients (CLL2-BIO-trial of the GCLLSG) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000590-39\/DE"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0027|cit27","unstructured":"A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-004985-27\/NL"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.24468","article-title":"A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"91","author":"Flinn I","year":"2016","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth J","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013474.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12032-014-0104-7","article-title":"How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation","volume":"31","year":"2014","journal-title":"Medical Oncology (Northwood, London, England)"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0031|cit31","unstructured":"CLL8: a randomised, phase III study to assess alemtuzumab consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL) who have responded to previous therapy www.isrctn.com\/ISRCTN63375144"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3324\/haematol.2018.193854","article-title":"Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia","volume":"104","author":"Kater A","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12032-010-9478-3","article-title":"Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia","volume":"28","author":"Kaufman M","year":"2011","journal-title":"Medical Oncology (Northwood, London, England)"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/1097-0142(19860915)58:6<1185::AID-CNCR2820580602>3.0.CO;2-H","article-title":"Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial","volume":"58","author":"Keller J","year":"1986","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000500164","article-title":"Pentostatin, cyclophosphamide, and rituximab followed by alemtuzumab for relapsed or refractory chronic lymphocytic leukemia: a phase 2 trial of the ECOG-Acrin Cancer Research Group (E2903)","volume":"142","author":"Kempin","year":"2019","journal-title":"Acta Haematologica"},{"issue":"8","key":"10.1002\/14651858.CD013474.pub2-BIB0036|cit36","first-page":"1405","article-title":"Feasibility of lenalidomide therapy for persistent chronic lymphocytic leukemia after allogeneic transplantation","volume":"23","author":"Khouri M","year":"2017","journal-title":"Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2008.16.4459","article-title":"Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses","volume":"27","author":"Lamanna","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2018030221","article-title":"Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia","volume":"3","author":"Lampson B","year":"2019","journal-title":"Blood Advances"},{"issue":"29","key":"10.1002\/14651858.CD013474.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","article-title":"Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101","volume":"28","author":"Lin T","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ajh.23983","article-title":"Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation\/maintenance, in previously untreated chronic lymphocytic leukemia","volume":"90","author":"Mato A","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0041|cit41","first-page":"1348","article-title":"Fludarabine + prednisone +\/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study","volume":"88","author":"Mauro F","year":"2003","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.seminhematol.2008.02.006","article-title":"Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy","volume":"45","author":"Moccia","year":"2008","journal-title":"Seminars In Hematology"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0043|cit43","first-page":"695","article-title":"Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine","volume":"87","author":"Montillo","year":"2002","journal-title":"Haematologica"},{"issue":"15","key":"10.1002\/14651858.CD013474.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2005.04.6037","article-title":"Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia","volume":"24","author":"Montillo","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0046|cit46","unstructured":"Low dose alemtuzumab for consolidation and maintenance of patients with b-cell chronic lymphocytic leukemia clinicaltrials.gov\/show\/NCT00336206"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0047|cit47","unstructured":"Campath maintenance in chronic lymphocytic leukemia clinicaltrials.gov\/show\/NCT00587847"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0048|cit48","unstructured":"Alemtuzumab + rituximab consolidation in CLL clinicaltrials.gov\/show\/NCT00771602"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0049|cit49","unstructured":"Lenalidomide following fludarabine\/rituximab (FR) in untreated chronic lymphocytic leukemia (CLL) clinicaltrials.gov\/show\/NCT00860457"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0050|cit50","unstructured":"Study of bendamustine\/rituxan induction chemotherapy with revlimid maintenance for relapsed\/refractory CLL and SLL clinicaltrials.gov\/show\/NCT00974233"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0051|cit51","unstructured":"Ofatumumab for minimal residual disease (MRD) and maintenance therapy clinicaltrials.gov\/show\/NCT01258933"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0052|cit52","unstructured":"Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fludarabine clinicaltrials.gov\/show\/NCT01392079"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0053|cit53","unstructured":"Chlorambucil + lenalidomide and lenalidomide maintenance in untreated elderly with chronic lymphocytic leukemia (CLL) clinicaltrials.gov\/show\/NCT01403246"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0054|cit54","unstructured":"Maintenance therapy: lenalidomide following bendamustine and rituximab induction therapy for chronic lymphocytic leukemia clinicaltrials.gov\/show\/NCT01465230"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0055|cit55","unstructured":"Ofatumumab, high dose methylprednisolone, ofatumumab and lenalidomide consolidative therapy for untreated CLL\/SLL clinicaltrials.gov\/show\/NCT01496976"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0056|cit56","unstructured":"Tolerance and efficacy of subcutanous low doses rituximab for CLL consolidation treatment clinicaltrials.gov\/show\/NCT01521689"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0057|cit57","unstructured":"Revlimid as consolidation treatment chronic lymphocytic leukemia clinicaltrials.gov\/show\/NCT01600053"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0058|cit58","unstructured":"Bendamustine and rituximab induction therapy and maintenance rituximab and lenalidomide in previously untreated CLL\/SLL clinicaltrials.gov\/show\/NCT01754857"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0059|cit59","unstructured":"Phase II study of bendamustine and rituximab induction chemoimmunotherapy followed by maintenance rituximab (Rituxan\u00ae) and lenalidomide (Revlimid\u00ae) in relapsed and refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) clinicaltrials.gov\/show\/NCT01754870"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0060|cit60","unstructured":"Ofatumumab induction and maintenance in elderly patients with poor risk CLL in the context of allogeneic transplantation clinicaltrials.gov\/show\/NCT01809847"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0061|cit61","unstructured":"CHAIROS study: a study of MabThera\/Rituxan (Rituximab) maintenance therapy in patients with b-cell chronic lymphocytic leukemia (CLL) naive to chemotherapy clinicaltrials.gov\/show\/NCT02013817"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0062|cit62","unstructured":"Bendamustine and rituximab (BR) as induction and maintenance in relapsed and refractory chronic lymphocytic leukemia clinicaltrials.gov\/show\/NCT03847727"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.V97.7.1929","article-title":"Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol","volume":"97","author":"Noy","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V86.4.1298.bloodjournal8641298","article-title":"Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy","volume":"86","author":"O'Brien","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia","volume":"98","author":"O'Brien S","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0066|cit66","first-page":"22","article-title":"Maintenance therapy for B-chronic lymphocytic leukemia","volume":"9","author":"O'Brien","year":"2011","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.13380","article-title":"Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients","volume":"170","author":"Osterborg","year":"2015","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/1042819031000067710","article-title":"CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas","volume":"44","author":"Pan","year":"2003","journal-title":"Leukemia & Lymphoma"},{"issue":"11","key":"10.1002\/14651858.CD013474.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"E310","DOI":"10.1002\/ajh.25968","article-title":"A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia","volume":"95","author":"Pleyer","year":"2020","journal-title":"American Journal of Hematology"},{"issue":"18","key":"10.1002\/14651858.CD013474.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai K","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajh.24693","article-title":"A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy","volume":"92","author":"Rosenthal","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdz053","article-title":"Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia","volume":"30","author":"Ruppert A","year":"2019","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.thj.6200361","article-title":"Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy","volume":"5","author":"Scaramucci","year":"2004","journal-title":"The Hematology Journal"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1702026","article-title":"Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study","volume":"24","author":"Schey","year":"1999","journal-title":"Bone Marrow Transplantation"},{"issue":"22","key":"10.1002\/14651858.CD013474.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","article-title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","volume":"119","author":"Sehn L","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3109\/10428194.2015.1067701","article-title":"Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission","volume":"57","author":"Shadman","year":"2016","journal-title":"Leukemia & Lymphoma"},{"issue":"20","key":"10.1002\/14651858.CD013474.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt T","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt T","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD013474.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman J","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"10232","key":"10.1002\/14651858.CD013474.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman J","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/10428190701225874","article-title":"Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy","volume":"48","author":"Srock","year":"2007","journal-title":"Leukemia & Lymphoma"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S2352-3026(16)30064-3","article-title":"Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial","volume":"3","author":"Strati","year":"2016","journal-title":"The Lancet Haematology"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.3324\/haematol.2017.171561","article-title":"Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia","volume":"102","author":"Strati","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/10428190310001615675","article-title":"Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia\/small lymphocytic lymphoma (B-CLL\/SLL)","volume":"45","author":"Thieblemont","year":"2004","journal-title":"Leukemia & Lymphoma"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41375-018-0313-8","article-title":"CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia","volume":"33","author":"Von Tresckow","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bjh.16264","article-title":"First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4","volume":"188","author":"Walewski","year":"2020","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.leu.2401892","article-title":"Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy","volume":"14","author":"Weiss M","year":"2000","journal-title":"Leukemia"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0088|cit88","first-page":"55","article-title":"Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma","volume":"79","author":"Zinzani P","year":"1994","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1600-0609.1997.tb00730.x","article-title":"Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma","volume":"59","author":"Zinzani P","year":"1997","journal-title":"European Journal of Haematology"},{"issue":"5-6","key":"10.1002\/14651858.CD013474.pub2-BIB0090|cit90","first-page":"437","article-title":"High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL--IGCI CLL-01 trial","volume":"30","author":"Jaksic","year":"1988","journal-title":"Nouvelle Revue Francaise d'Hematologie"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0091|cit91","unstructured":"Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab clinicaltrials.gov\/show\/NCT03280160"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s13063-017-2107-0","article-title":"GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II\/III randomised controlled trial","volume":"18","author":"Oughton J","year":"2017","journal-title":"Trials"},{"issue":"24","key":"10.1002\/14651858.CD013474.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-05-502773","article-title":"Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia","volume":"122","author":"Abrisqueta","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"265840","DOI":"10.1155\/2014\/265840","article-title":"Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells","volume":"1","author":"Acebes-Huerta","year":"2014","journal-title":"Biomed Research International"},{"issue":"13","key":"10.1002\/14651858.CD013474.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD013474.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Barth","year":"2012","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3747\/co.22.2119","article-title":"Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis","volume":"22","author":"Beauchemin","year":"2015","journal-title":"Current Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00277-014-2117-x","article-title":"NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment","volume":"93","author":"Bo","year":"2014","journal-title":"Annals of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","article-title":"Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab","volume":"186","author":"Bologna","year":"2011","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"New England Journal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/10428190903150839","article-title":"Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901","volume":"50","author":"Byrd","year":"2009","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD013474.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2014-07-586610","article-title":"Obinutuzumab (GA101) in relapsed\/refractory chronic lymphocytic leukemia: final data from the phase 1\/2 GAUGUIN study","volume":"124","author":"Cartron","year":"2014","journal-title":"Blood"},{"issue":"34","key":"10.1002\/14651858.CD013474.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo,\u2028bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or\u2028small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013474.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S2352-3026(17)30168-0","article-title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Chanan-Khan","year":"2017","journal-title":"Lancet Haematology"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/bjh.13957","article-title":"Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study","volume":"173","author":"Chang","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD013474.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3109\/10428194.2013.796050","article-title":"Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group","volume":"54","author":"Cramer","year":"2013","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ejh.12678","article-title":"Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)","volume":"96","author":"Cramer","year":"2016","journal-title":"European Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/fon-2017-0442","article-title":"CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia","volume":"14","author":"Cramer","year":"2018","journal-title":"Future Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"543\u201354","DOI":"10.3324\/haematol.2019.223693","article-title":"Bendamustine followed by ofatumumab andibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)","volume":"106","author":"Cramer","year":"2021","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0120|cit120","unstructured":"US Department of Health and Human Services Common terminology criteria for adverse events (CTCAE) Version 5.0 ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101","volume":"10","author":"Dalle","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S2352-3026(17)30235-1","article-title":"Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study","volume":"5(2)","author":"Dartigeas","year":"2018","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0123|cit123","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"26","key":"10.1002\/14651858.CD013474.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1002\/14651858.CD013474.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"issue":"7109","key":"10.1002\/14651858.CD013474.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"629\u201334","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013474.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303.","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0130|cit130","unstructured":"EndNote X8.1 Clarivate"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.leukres.2009.07.008","article-title":"Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years","volume":"34","author":"Faderl","year":"2010","journal-title":"Leukemia Research"},{"issue":"11","key":"10.1002\/14651858.CD013474.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1016\/S2352-3026(17)30171-0","article-title":"Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study","volume":"4","author":"Fink","year":"2017","journal-title":"Lancet Haematology"},{"issue":"26","key":"10.1002\/14651858.CD013474.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ajh.23668","article-title":"Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients","volume":"89","author":"Foa","year":"2014","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD013474.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/cancers12051328","article-title":"Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas","volume":"12","author":"George","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0140|cit140","unstructured":"GetData Graph Digitizer Fedorov 2019"},{"issue":"25","key":"10.1002\/14651858.CD013474.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0142|cit142","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(16)30045-X","article-title":"Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial","volume":"3","author":"Greil","year":"2016","journal-title":"Lancet Haematology"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"20","key":"10.1002\/14651858.CD013474.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9747","key":"10.1002\/14651858.CD013474.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajh.23491","article-title":"Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment","volume":"88","author":"Hallek","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"23","key":"10.1002\/14651858.CD013474.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2013-05-498287","article-title":"Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies","volume":"122","author":"Hallek","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"806398","DOI":"10.1182\/blood-2017-09-806398","article-title":"Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia","volume":"09","author":"Hallek","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0155|cit155","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0156|cit156","unstructured":"Higgins JPT Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0157|cit157","unstructured":"Howlader N Noone AM Krapcho M Miller D Bishop K Altekruse SF SEER cancer statistics review, 1975\u20132013 seer.cancer.gov\/archive\/csr\/1975_2013\/"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0158|cit158","first-page":"193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina T","year":"2006","journal-title":"Sychological Methods"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1371\/journal.pmed.0040215","article-title":"Why most published research findings are false: author's reply to Goodman and Greenland","volume":"4","author":"John P A","year":"2007","journal-title":"PLOS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/13543784.2017.1313230","article-title":"Lenalidomide in the treatment of chronic lymphocytic leukemia","volume":"26","author":"Itchaki","year":"2017","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3109\/10428194.2013.788179","article-title":"Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101","volume":"54","author":"Jones","year":"2013","journal-title":"Leukemia & Lymphoma"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematology"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncology"},{"issue":"14","key":"10.1002\/14651858.CD013474.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1182\/blood-2014-05-578286","article-title":"How does lenalidomide target the chronic lymphocytic leukemia microenvironment?","volume":"124","author":"Kater","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12032-010-9478-3","article-title":"Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia","volume":"28","author":"Kaufman","year":"2011","journal-title":"Medical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/1097-0142(19860915)58:6<1185::AID-CNCR2820580602>3.0.CO;2-H","article-title":"Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial","volume":"58","author":"Keller","year":"1986","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013474","article-title":"Maintenance therapy for chronic lymphocytic leukaemia","author":"Lin","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1371\/journal.pone.0226879","article-title":"A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia","volume":"3","author":"Lee","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0169|cit169","unstructured":"Lefebvre C Manheimer E Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-07-6663","article-title":"Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Research"},{"issue":"24","key":"10.1002\/14651858.CD013474.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1182\/blood-2009-06-225474","article-title":"Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma","volume":"114","author":"Li","year":"2009","journal-title":"Blood"},{"issue":"29","key":"10.1002\/14651858.CD013474.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","article-title":"Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101","volume":"28","author":"Lin","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1200\/JCO.2013.53.8421","article-title":"Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?","volume":"32","author":"Mertens","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1186\/s12885-022-10223-0","article-title":"Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors","volume":"22","author":"Mkhwanazi","year":"2022","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1006\u201312","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/1097-0142(19851115)56:10<2369::AID-CNCR2820561004>3.0.CO;2-N","article-title":"Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone","volume":"56","author":"Montserrat","year":"1985","journal-title":"Cancer"},{"issue":"21","key":"10.1002\/14651858.CD013474.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1001\/jama.2014.14553","article-title":"Chronic lymphocytic leukemia: a clinical review","volume":"312","author":"Nabhan","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0179|cit179","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas 2021 v5.0 www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13063-017-2107-0","article-title":"GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II\/III randomised controlled trial","volume":"18","author":"Oughton","year":"2017","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0182|cit182","first-page":"22","article-title":"Maintenance therapy for B-chronic lymphocytic leukemia","volume":"9","author":"O\u2019Brien","year":"2011","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11136-017-1718-y","article-title":"International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia","volume":"27","author":"Poll-Franse","year":"2018","journal-title":"Quality of Life Research"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.4049\/jimmunol.1202588","article-title":"Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties","volume":"190","author":"Rafiq","year":"2013","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1172\/JCI35017","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0189|cit189","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"8","key":"10.1002\/14651858.CD013474.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2174\/1568009616666160408145741","article-title":"Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia","volume":"16","author":"Riches","year":"2016","journal-title":"Current Cancer Drug Targets"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood-2009-10-251249","article-title":"Improving FCR immunochemotherapy in CLL","volume":"115","author":"Robak","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD013474.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2013-10-534131","article-title":"Maintenance in CLL","volume":"122","author":"Robak","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD013474.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/ejh.13042","article-title":"Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG \u2013 CLL4 (ML21283) trial","volume":"100","author":"Robak","year":"2018","journal-title":"European Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD013474.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0197|cit197","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD013474.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"issue":"10232","key":"10.1002\/14651858.CD013474.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0201|cit201","first-page":"25","article-title":"Management of patients with relapsed chronic lymphocytic leukemia","volume":"12","author":"Shindiapina","year":"2016","journal-title":"American Journal of Hematology and Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1309\/AJCPLIR4GZWX3XKA","article-title":"Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia","volume":"139","author":"Siddon","year":"2013","journal-title":"American Journal of Clinical Patholology"},{"issue":"1","key":"10.1002\/14651858.CD013474.pub2-BIB0203|cit203","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0204|cit204","unstructured":"Number of new cases and age-standardized rates of primary cancer, by cancer type and sex www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310074701"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0205|cit205","unstructured":"Sterne JA Egger M Moher D on behalf of the Cochrane Bias Methods Group Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/asheducation-2010.1.481","article-title":"Understanding and managing ultra high-risk chronic lymphocytic leukemia","volume":"1","author":"Stilgenbauer","year":"2010","journal-title":"Hematology. American Society of Hematology. Education Program"},{"issue":"12","key":"10.1002\/14651858.CD013474.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"e494","DOI":"10.3324\/haematol.2017.171561","article-title":"Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia","volume":"102","author":"Strati","year":"2017","journal-title":"Haematologica"},{"issue":"20","key":"10.1002\/14651858.CD013474.pub2-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD013474.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1016\/S2352-3026(16)30046-1","article-title":"Maintenance therapy in CLL: resolving the controversy","volume":"3","author":"Tam C","year":"2016","journal-title":"The Lancet Hematology"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1182\/blood-2021-148457","article-title":"SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus Bendamustine + Rituximab (BR) in patients with Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"138","author":"Tam","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunology Today"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"20","key":"10.1002\/14651858.CD013474.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Thompson","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood-2015-08-634816","article-title":"Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013474.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"8","key":"10.1002\/14651858.CD013474.pub2-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"2125\u20138","DOI":"10.1038\/s41375-022-01629-7","article-title":"Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial","volume":"36","author":"Tresckow","year":"2022","journal-title":"Leukemia"},{"issue":"4678","key":"10.1002\/14651858.CD013474.pub2-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"issue":"13","key":"10.1002\/14651858.CD013474.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"Van Oers","year":"2015","journal-title":"Lancet Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013474.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2016.1154956","article-title":"Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) \u2013 a systematic review and meta-analysis of randomized trials","volume":"57","author":"Vidal","year":"2016","journal-title":"Leukemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD013474.pub2-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission \u2013 experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"issue":"18","key":"10.1002\/14651858.CD013474.pub2-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013474.pub2-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"293","DOI":"10.6004\/jnccn.2017.0030","article-title":"NCCN Guidelines Insights: Chronic Lymphocytic Leukemia\/Small Lymphocytic Leukemia, Version 1.2017","volume":"15","author":"Wierda","year":"2017","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"14","key":"10.1002\/14651858.CD013474.pub2-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD013474.pub2-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1097\/HS9.0000000000000175","article-title":"From Biology to Therapy: The CLL Success Story","volume":"3","author":"Yosifov","year":"2019","journal-title":"Hemasphere"},{"issue":"3","key":"10.1002\/14651858.CD013474.pub2-BIB0227|cit227","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with\u2028relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3,\u2028randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T02:48:35Z","timestamp":1730774915000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013474.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":227,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013474.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}